Furthermore, the cells exhibited heightened DNA damage and raised apoptosis bith in vitro and in vivo, suggesting that the PARP-1 inhibitor GPI-15427 could enhance the susceptibility of HNSCC tumors to radiation therapy (Güster et al., 2014). This evidence concerns the gene PARP1 and head and neck squamous cell carcinoma.